M&A Deal Summary

Roche Acquires Santaris Pharma A/S

On August 6, 2014, Roche acquired life science company Santaris Pharma A/S from Gilde Healthcare for 250M USD

Acquisition Highlights
  • This is Roche’s 12th transaction in the Life Science sector.
  • This is Roche’s 18th largest (disclosed) transaction.
  • This is Roche’s 1st transaction in Denmark.

M&A Deal Summary

Date 2014-08-06
Target Santaris Pharma A/S
Sector Life Science
Buyer(s) Roche
Sellers(s) Gilde Healthcare
Deal Type Add-on Acquisition
Deal Value 250M USD

Target

Santaris Pharma A/S

Horsholm, Denmark
website
Santaris Pharma A/S is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases that are difficult-to-treat with conventional drug modalities. Santaris uses its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise to pioneer next-generation antisense product candidates.

Search 193,924 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland

website


Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 63.3B CHF (2022)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.


DEAL STATS #
Overall 19 of 42
Sector (Life Science) 12 of 29
Type (Add-on Acquisition) 17 of 35
Country (Denmark) 1 of 1
Year (2014) 2 of 5
Size (of disclosed) 18 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-06-02 Genia Technologies

Mountain View, California, United States

Genia is developing a potentially disruptive next generation sequencing technology with integrated circuits enabling massively parallel, single-molecule DNA sequencing.

Buy $125M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-24 InterMune

Brisbane, California, United States

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Buy $8.3B

Seller(S) 1

SELLER
DESCRIPTION

Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest up to €30 million in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.


DEAL STATS #
Overall 11 of 30
Sector (Life Science) 8 of 16
Type (Add-on Acquisition) 6 of 15
Country (Denmark) 1 of 3
Year (2014) 2 of 6
Size (of disclosed) 1 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-07 Vapotherm

Exeter, New Hampshire, United States

Vapotherm, Inc. is a privately held manufacturer of advanced respiratory care devices based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-26 Sapiens Steering Brain Stimulation

Munich, Germany

Sapiens Steering Brain Stimulation GmbH is developing a Deep Brain Stimulation (DBS) system for patients suffering from brain disorders such as Parkinson’s disease. Sapiens’ innovative solution is an advanced DBS lead with 40 individual stimulation points.

Sell $200M